250 Summer St 3rd Fl
160 articles with CureVac
CureVac Announces Voting Results of Extraordinary General Meeting
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the voting results of the Company's extraordinary general meeting.
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
CureVac N.V. announced the closing of its follow-on public offering of 27,027,028 common shares, at a public offering price of $9.25 per common share, for total gross proceeds of approximately $250 million before deducting underwriting discounts and commissions and offering expenses payable by CureVac.
CureVac Announces Proposed Public Offering of Common Shares - February 07, 2023
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that it intends to offer $200 million of its common shares in an underwritten public offering.
CureVac Welcomes Myriam Mendila as New Chief Development Officer
CureVac N.V. today announced that Myriam Mendila has taken up her role as CureVac's Chief Development Officer, as previously announced.
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced its inclusion in the second annual "Innovation Momentum: The Global Top 100" report by LexisNexis®.
CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
CureVac N.V. announced that Chief Executive Officer Franz-Werner Haas, Chief Financial Officer Pierre Kemula and Interim Chief Development Officer Ulrike Gnad-Vogt sold an aggregate of 103,775 CureVac common shares.
August 1 is RNA Day. BioSpace takes a look at recent breakthroughs in RNA therapeutics, and the vast potential of the "vital biological molecule."
“The applications for mRNA are quite broad, because, basically, you are giving information to a cell to make any protein you want," CureVac CFO Pierre Kemula told BioSpace.
Pfizer and BioNTech initiated a Phase II trial of an enhanced COVID-19 vaccine while fending off lawsuits against CureVac and Alnylam over their technology.
Battle of the Patents: Daiichi Sankyo, Seagen, Alnylam, CureVac, Pfizer, BioNTech & Moderna
7/20/2022The LPN technology used in the mRNA COVID-19 vaccines has been the target of numerous patent challenges. Here's a look at recent biopharma patent disputes.
Moderna has dosed its first participant in a Phase I clinical trial of mRNA-1215, a vaccine designed to fight the Nipah virus (NiV), a virus contracted in humans through animals.
CureVac has filed a lawsuit against BioNTech and two of its subsidiaries for allegedly infringing on its intellectual property rights over mRNA technology used in the COVID-19 vaccine.
Even though the COVID-19 pandemic appears to be under control, it's clear that it's not over, with the rise of more subvariants. Read on for more details.
CureVac Announces Voting Results of General Meeting - June 22, 2022
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the voting results of the Company's annual general meeting.
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
CureVac N.V. announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid announced that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022.
Germany’s CureVac is partnering with Belgium’s myNEO to identify specific cancer antigens in order to develop novel mRNA immunotherapies for cancer vaccines.
GlaxoSmithKline exceeded expectations for its first-quarter sales and earnings forecasts. This was largely driven by its sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and its Shingrix vaccine against shingles.
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
CureVac N.V. and GSK today announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany.
The FDA is looking at revising the current vaccine strategy and emphasizing that individuals need to consider their own risk tolerance. For that and more, continue reading.